Every 8-K that PDS Biotechnology Corporation (PDSB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PDSB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PDSB filings page.
PDS Biotechnology Corp (PDSB) entered into a private PIPE financing with accredited investors, structured as an Initial Closing and a contingent Milestone Closing, for up to $22.55 million in equity and warrant securities. At the Initial Closing, PDS Biotech expects to raise approximately $11.55 million through units of common stock or pre-funded warrants plus accompanying one-year common warrants priced at $0.2825 per share unit and $0.28217 per pre-funded unit. Nant Capital and AB Group have committed a further $10 million and $1 million, respectively, at $0.22 per share (or $0.21967 per pre-funded warrant) upon submission of a registrational Phase 3 protocol for PDS0301. The company discloses that the maximum number of common shares issuable from the private placement, including warrant exercises, is 111,327,435 shares.
Nant will have the right to designate two directors, including Dr. Patrick Soon-Shiong, while it holds at least 15% of the outstanding common stock, and the board size has been increased from six to eight seats to accommodate these designees. PDS Biotech committed to maintain Nasdaq listing, reserve sufficient shares for warrant exercises, register the resale of the new securities with liquidated-damages protections for investors, and apply proceeds to repay indebtedness and fund working capital and clinical development. The company also granted NantWorks a one-year exclusive right to negotiate a potential exclusive license for its PDS0101 program.
PDS Biotechnology Corp (PDSB) reports that on August 31, 2026 it entered into a First Amendment to Promissory Note with YA II PN, Ltd., amending a promissory note originally issued on June 15, 2026 with an original principal amount of $6,000,000.
The amendment document is filed as an exhibit, but the specific modified terms are not described in the body of the report.
PDS Biotechnology Corp (symbol PDSB) reports that its Board approved a significant reduction in force to align operating expenses with strategic priorities and focus on advancing its PDS0301 program. The plan, approved on August 6, 2026, is expected to impact approximately 36% of the workforce and be substantially completed during the third quarter of 2026.
The company expects to record a one-time charge of about $842,000 in the third quarter of 2026 for employee separation benefits, all anticipated to be cash expenditures. PDS Biotechnology also states that additional, currently uncontemplated costs may arise and that actual results may differ materially from its estimates. Separately, effective August 21, 2026, the company terminated Chief Operating Officer Stephan Toutain without cause. Under his employment agreement, he is eligible for severance equal to 12 months of base salary, paid in installments, plus up to 12 months of company-paid COBRA health-care contributions, subject to signing a separation agreement and release of claims.
PDS Biotechnology Corp (PDSB) reported that Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective September 12, 2026, to pursue other professional endeavors. He acknowledged that his resignation is not due to any disagreement regarding operations, policies, or practices.
Effective the same date, the board appointed Janetta Trochimiuk, the company’s Controller, as interim Principal Accounting Officer and Frank Bedu-Addo, Ph.D., President and Chief Executive Officer, as interim Principal Financial Officer. Ms. Trochimiuk, age 63, has over 25 years of experience in senior finance roles and will continue as Controller with an annual base salary of $279,519.57, remaining eligible for equity awards under the Third Amended and Restated 2014 Equity Incentive Plan.
PDS Biotechnology Corporation reported results of its 2026 annual stockholders meeting held on August 10, 2026. Stockholders approved an amendment to the Eighth Amended and Restated Certificate of Incorporation increasing authorized common stock from 150,000,000 to 300,000,000 shares; the charter is unchanged otherwise.
Two Class B directors, Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified the appointment of KPMG US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Of 55,815,653 shares entitled to vote, 31,594,722 shares (approximately 56.60%) were represented in person or by proxy, constituting a quorum for conducting business.
PDS Biotechnology Corporation reported second quarter 2026 results and outlined a strategic refocus. Management is prioritizing lead program PDS0301, a tumor-targeted IL-12 immunocytokine, and will cease further internal investment in PDS0101, including discontinuation of the VERSATILE-003 Phase 3 trial, while seeking partnerships or other externally funded paths for PDS0101.
For the quarter ended June 30, 2026, net loss was $9.8 million, or $0.18 per share, versus $9.4 million, or $0.21 per share, a year earlier. Research and development expenses declined to $3.3 million from $4.2 million, and general and administrative expenses declined to $3.2 million from $3.4 million, leading to total operating expenses of $6.5 million versus $7.6 million. Net interest expense increased to $3.3 million, largely due to a non-cash loss on retirement of debt.
At June 30, 2026, cash and cash equivalents were $5.6 million. Working capital was $(5.3) million, total stockholders’ equity was $(3.6) million, and accumulated deficit reached $233.7 million, reflecting ongoing losses despite reduced operating spending.
PDS Biotechnology Corporation furnished a shareholder letter outlining a strategic refocus of its oncology pipeline. The company plans to prioritize PDS0301, a tumor-targeted IL-12 immunocytokine, particularly in metastatic colorectal cancer, and to seek strategic partnerships or other externally funded opportunities for PDS0101.
Management reported Phase 2 data in metastatic microsatellite stable and mismatch repair-proficient colorectal cancer with liver metastases, citing a 71% objective response rate at 6 months and an 80% 24-month survival rate, with safety observed in more than 380 treated patients. Internal investment in the PDS0101 Phase 3 VERSATILE-003 trial will cease, and the trial will be discontinued. A randomized Phase 2b trial of PDS0301 has been designed with FDA feedback, targeting meaningful data generation over the next 18 to 24 months. The company also states it will announce financial results for the quarter ended June 30, 2026, on August 13, 2026.
PDS Biotechnology Corporation reported receiving a Nasdaq Listing Qualifications deficiency notice because the closing bid price of its common stock has been below the $1.00 minimum required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The notice has no immediate effect on trading, and the shares continue to trade on The Nasdaq Capital Market under the symbol PDSB.
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has a 180-day compliance period, until January 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If compliance is not regained, PDS Biotechnology may qualify for an additional 180-day period but ultimately faces potential delisting, with the right to appeal any delisting decision. The company plans to monitor its share price and may consider actions such as a reverse stock split to address the deficiency.
PDS Biotechnology Corporation closed a financing with YA II PN, Ltd., issuing a $6,000,000 Promissory Note, sold for $5,760,000, and a Warrant to purchase 2,158,274 common shares at $1.1824 per share. The note matures 12 months after the June 15, 2026 closing and carries 10% annual interest.
The company also put in place a Sales Agreement for an “at-the-market” stock offering of up to $50,000,000 of common shares, paying a 3.0% commission on sales. On the closing date, it redeemed in full its prior Senior Secured Convertible Debentures at 103% of principal plus accrued interest, extinguishing related rights.
PDS Biotechnology Corporation has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. The meeting date is more than 30 days after the anniversary of the 2025 Annual Meeting, so the company has set a special deadline for stockholder proposals.
Stockholders seeking to include proposals in the proxy materials under SEC Rule 14a-8 must submit them by June 25, 2026. Eligible proposals must comply with SEC rules and should be sent to the Corporate Secretary at the company’s Princeton, New Jersey headquarters.
PDS Biotechnology Corporation reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price rule. Nasdaq had previously notified the company that its common stock closed below the required $1.00 per share for 30 consecutive business days, triggering a deficiency notice. On June 2, 2026, Nasdaq informed PDS Biotechnology that the company once again meets the Minimum Bid Price Requirement and that the compliance matter is now closed.
PDS Biotechnology reported first quarter 2026 results and a clinical pipeline update. Net loss was about $7.3 million, or $0.13 per share, improving from a loss of $8.5 million, or $0.21 per share, a year earlier.
Research and development expenses fell to $3.5 million from $5.8 million, mainly from lower clinical and manufacturing costs, while general and administrative expenses edged down to $3.1 million. Cash and cash equivalents were $21.7 million as of March 31, 2026, with long‑term debt of $10.6 million and stockholders’ equity of $3.9 million.
Management highlighted progress on the amended VERSATILE‑003 Phase 3 trial in HPV16‑positive head and neck cancer and ongoing Phase 2 studies of PDS01ADC in metastatic colorectal and advanced castration‑resistant prostate cancers.
PDS Biotechnology Corporation entered into a financing deal with YA II PN, LTD., agreeing to issue a $6,000,000 promissory note and a warrant for 2,158,274 common shares at an exercise price of $1.1824 per share. The note, sold for $5,760,000, carries 10% annual interest, matures 12 months after closing, and can become convertible at a discount to market prices if the company is late on payments, subject to ownership and Nasdaq 19.99% caps. PDS will also enter an at-the-market sales agreement with Yorkville Securities, LLC and has delivered notices to redeem its existing senior secured convertible debentures at 103% of principal plus interest on June 12, 2026, using cash.
PDS Biotechnology filed an 8-K to share an updated April 2026 corporate presentation highlighting its cancer immunotherapy pipeline. The deck focuses on lead HPV16-targeted drug PDS0101, which showed a median overall survival of 39.3 months in recurrent/metastatic head and neck cancer, compared with a 12–18 month benchmark for Keytruda-based regimens. In a prior Phase 2 study, PDS0101 plus pembrolizumab achieved a 77.4% disease control rate and a 35.8% overall response rate, with 21% of patients experiencing 90–100% tumor regression.
The company is running the VERSATILE‑003 pivotal Phase 3 trial in first-line HPV16‑positive recurrent/metastatic head and neck cancer, with FDA alignment on progression-free survival as an interim primary endpoint for an accelerated approval pathway. Beyond PDS0101, the presentation details tumor-targeting IL‑12 antibody-drug conjugate PDS01ADC in multiple Phase 2 trials across colorectal, prostate and liver-associated cancers, and outlines upcoming data readouts through 2027.
PDS Biotechnology Corporation reported positive interim results from Stage 1 of an NCI-led Phase 2 trial of its tumor-targeted IL‑12 immunocytokine PDS01ADC in metastatic colorectal cancer with liver metastases. In nine patients who had failed at least one prior chemotherapy line, adding PDS01ADC to hepatic artery infusion pump therapy produced a 78% objective response rate, compared with 35% in a parallel trial without PDS01ADC. The two-year survival rate exceeded 80%, versus about 35% in the parallel trial, in this largely immunotherapy‑resistant microsatellite stable or mismatch repair‑proficient population.
PDS Biotechnology reported full-year 2025 results and detailed progress in its cancer immunotherapy pipeline. Net loss narrowed to $34.5 million, or $0.74 per share, from $37.6 million, or $1.03, in 2024 as operating expenses declined.
Research and development spending fell to $19.0 million and general and administrative expenses to $12.5 million, bringing total operating expenses down to $31.5 million. Cash and cash equivalents were $26.7 million at year-end, with total stockholders’ equity of $9.3 million and long-term debt of $11.7 million.
The company updated its PDS0101 Phase 3 VERSATILE-003 trial, incorporating progression-free survival as an interim primary endpoint, which it expects will shorten trial duration and reduce costs while keeping overall survival for full approval. PDS Biotech also highlighted new U.S. and Japanese patents that extend Versamune® platform protection into the 2040s.
PDS Biotechnology Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price required to remain listed on The Nasdaq Capital Market. The closing bid has stayed below $1.00 for 30 straight business days.
The stock continues trading under the symbol PDSB while the company has 180 calendar days, until August 24, 2026, to regain compliance by posting a closing bid of at least $1.00 for at least 10 consecutive business days. If it still fails to comply, Nasdaq may grant a second 180‑day period if other listing standards are met.
If compliance is not restored, the shares could ultimately be delisted, although the company would have the right to appeal any delisting decision. PDS Biotechnology plans to monitor its share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.
PDS Biotechnology Corporation filed a Form 8-K to share its updated February 2026 corporate presentation. The deck focuses on PDS0101, a Versamune-based immunotherapy targeting HPV16-positive head and neck cancers, and PDS01ADC, a tumor-targeted IL-12 immunocytokine.
PDS0101 plus pembrolizumab in first-line HPV16-positive recurrent/metastatic head and neck cancer showed a median overall survival of 39.3 months, compared with a 12–18 month benchmark for pembrolizumab-based regimens, a 77.4% disease control rate, and a 35.8% objective response rate. Treatment-related adverse events were mostly grade 1–2.
The company highlights a pivotal Phase 3 VERSATILE-003 trial with progression-free survival as the primary endpoint for accelerated approval, multiple Phase 2 studies of PDS01ADC across prostate, colorectal, and liver-associated cancers, and more than 12 patent families providing PDS0101 exclusivity through 2042/2043 in key global markets.
PDS Biotechnology Corporation has adopted an amended protocol for its Phase 3 VERSATILE-003 trial of PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer. The amendment designates progression-free survival (PFS) as an interim primary endpoint to support a potential accelerated approval pathway, while median overall survival (mOS) remains the primary endpoint for full approval. After the FDA’s standard 30-day review of the amended protocol to the IND without objection, the company is proceeding under the new design, which it believes may shorten trial duration and make the study more cost efficient.
PDS Biotechnology Corporation reported that results from a National Cancer Institute-led study of its investigational Interleukin-12 (IL-12) tumor-targeted immunocytokine, PDS01ADC, were presented at a major prostate cancer research conference. The presentation took place at an American Association of Cancer Research special conference in Boston, covering meetings held January 20-22, 2026.
The company issued a press release on January 28, 2026 to share this update, and that release is attached as an exhibit to the filing, providing more detail on the study and its findings.
PDS Biotechnology Corporation reported that the U.S. Patent Office has issued a Notice of Allowance for a patent covering its lead asset, PDS0101. A Notice of Allowance means the patent application has been approved and a patent is expected to be granted once final formalities and fees are completed.
The company highlighted this development in a press release attached to the report. Strengthening patent protection around a lead drug candidate can help secure future commercial exclusivity if the product is successfully developed and approved, although this filing does not provide clinical or financial details.
PDS Biotechnology Corporation reported that it has submitted a protocol amendment to the U.S. Food and Drug Administration for its Phase 3 VERSATILE-003 clinical trial of PDS0101. The amendment would make progression free survival the primary endpoint that can be evaluated earlier with significant statistical power, which may provide a basis for accelerated approval of PDS0101. Median overall survival remains the primary endpoint for full approval, consistent with the FDA’s original recommendation.
PDS Biotechnology (PDSB) filed an 8-K stating it furnished a press release with updates to its clinical programs and its financial results for the quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1. The company notes the information is “furnished” and not “filed” under the Exchange Act and is not subject to Section 18 liability or incorporated by reference except as expressly set forth.
PDS Biotechnology (PDSB) entered a registered offering, agreeing to sell 5,741,000 shares at $0.91, 59,000 pre-funded warrants (exercise price $0.0001), and 5,800,000 common warrants at $1.00 per share. The common warrants are exercisable beginning six months after issuance and expire five years from initial exercise.
The transaction is expected to generate gross proceeds of up to approximately $11.1 million, assuming full cash exercise of the common warrants, with net proceeds up to approximately $10.4 million. The company plans to use proceeds for research and development and general corporate purposes. Directors and executive officers agreed to 60-day lock-ups; the company agreed to a 45-day no-issuance period and a six-month restriction on variable rate transactions, with ATM activity permitted after 45 days under an existing agreement.
PDS also agreed to amend existing warrants covering up to 5,948,334 shares, reducing the exercise price from $1.50 to $1.00, exercisable starting six months after closing. Craig-Hallum will act as placement agent for a 6.0% cash fee on shares and pre-funded warrants, plus up to $100,000 in expenses. The offering is under an effective Form S-3, supplemented by a prospectus dated November 12, 2025.
PDS Biotechnology (PDSB) filed an 8-K noting a press release about positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The presentations focus on immune-driven mechanisms and biomarkers tied to the company’s investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC.
The company states these findings help explain the programs’ strong clinical activity. A full copy of the press release is furnished as Exhibit 99.1.
PDS Biotechnology (PDSB) filed an 8-K announcing a regulatory step for its lead immunotherapy. The company said it has requested a meeting with the U.S. Food and Drug Administration to explore an expedited approval pathway for PDS0101 in HPV16+ head and neck cancer. The announcement was made via a press release furnished as Exhibit 99.1.
This update signals the company’s intent to discuss potential accelerated routes with regulators, which, if granted in the future, could affect how quickly PDS0101 reaches patients. The filing does not include additional program, timing, or financial details beyond the meeting request.
PDS Biotechnology Corporation filed an 8-K stating that on September 18, 2025 it issued a press release detailing a sub-analysis of the cohort of patients with low PD-L1 expression (CPS 1-19) drawn from the final data of its VERSATILE-002 Phase 2 clinical trial. The filing itself does not include the press release text or any efficacy, safety, or numerical outcome data; it only identifies the press release as Exhibit 99.1 and incorporates it by reference. This disclosure notifies investors that the company is reporting subgroup findings for a defined low PD-L1 population but provides no performance metrics, so readers must consult the Exhibit for results.
PDS Biotechnology Corporation filed a current report to note that it has updated its corporate presentation deck. The new presentation, dated August 2025, is provided as Exhibit 99.1 and is incorporated by reference, meaning it is intended to be used as part of the company’s formal public disclosures. The filing does not describe financial results or new transactions, but signals that the company is refreshing the materials it uses to communicate its business, pipeline, and strategy to the market.
PDS Biotechnology Corporation filed a report describing that it has issued a press release with final topline survival data from its VERSATILE-002 Phase 2 clinical trial. This study evaluated its immunotherapy candidate PDS0101 (Versamune® HPV) in combination with Keytruda® (pembrolizumab) for patients with HPV16-positive, first-line recurrent or metastatic head and neck squamous cell cancer. The company has attached the full press release as Exhibit 99.1 for more detailed clinical results.
PDS Biotechnology Corporation filed a current report stating that it issued a press release on August 13, 2025 providing an update on its clinical programs and financial results for the quarter ended June 30, 2025. The report explains that the press release is attached as Exhibit 99.1 and is being treated as information that is furnished rather than filed under securities law, which affects the level of legal liability associated with it. The filing itself does not detail the results or clinical data, but directs readers to the attached press release for those specifics.
PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck. The new June 2025 slide deck is furnished as Exhibit 99.1 and incorporated by reference into the filing. No financial statements, earnings figures, strategic transactions, or other material events were disclosed. Investors should review the furnished deck for any updated development timelines or clinical program highlights; however, the 8-K itself contains no additional quantitative or qualitative information.